Votrient
NDC Package 0078-0670-66

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Votrient is pazopanib is used to treat certain types of cancer (kidney, soft tissue sarcoma). Marketed by Novartis Pharmaceuticals Corporation, this product is identified by NDC 0078-0670 and is authorized under FDA application NDA022465.

Identification & Billing

NDC Package Code
0078-0670-66
Package Description
120 TABLET, FILM COATED in 1 BOTTLE
Product Code
0078-0670
11-Digit Billing Format
00078067066

Clinical Specifications

Proprietary Name
Votrient
Dosage Form
-
Usage Information
Pazopanib is used to treat certain types of cancer (kidney, soft tissue sarcoma). Pazopanib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by decreasing the blood supply to the cancer tumor to slow tumor growth. This medication should not be used in children, especially younger than 2 years of age, because of the risk of serious side effects.

Regulatory & Marketing

Labeler Name
Novartis Pharmaceuticals Corporation
FDA Application #
NDA022465
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
07-12-2016
End Marketing Date
01-03-2025
Listing Expiration
01-03-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0078-0670-66 identifies a specific commercial package of 120 tablet, film coated in 1 bottle of Votrient, labeled by Novartis Pharmaceuticals Corporation. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Novartis Pharmaceuticals Corporation on July 12, 2016. The current certification is valid through January 03, 2025.

What are the primary indications for this medication?

Pazopanib is used to treat certain types of cancer (kidney, soft tissue sarcoma). Pazopanib belongs to a class of drugs known as tyrosine kinase inhibitors. It works by decreasing the blood supply to the cancer tumor to slow tumor growth. This medication should not be used in children, especially younger than 2 years of age, because of the risk of serious side effects.

How is this Novartis Pharmaceuticals Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00078067066. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0078-0670-66
11-Digit CMS (5-4-2)
00078-0670-66

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.